Antifungal prophylaxis for cornea

Abstract

The technology described herein is directed to ionic liquids for using the treatment or prevention of fungal infections.

What is claimed herein is: 
     
         1 . A composition comprising at least one ionic liquid comprising a quaternary ammonium cation and a undecanoic acid anion. 
     
     
         2 . The composition of  claim 1 , wherein the cation has a molar mass equal to or greater than choline. 
     
     
         3 . The composition of  claim 1 , wherein the quaternary ammonium has the structure of NR 4   +  and at least one R group comprises a hydroxy group. 
     
     
         4 . The composition of  claim 1 , wherein the cation is choline, C1, C6, or C7. 
     
     
         5 . The composition of  claim 1 , wherein the ionic liquid comprises a ratio of cation to anion of from 2:1 to 1:10. 
     
     
         6 . The composition of  claim 1 , wherein the ionic liquid comprises a ratio of cation to anion of from 2:1 to 1:2. 
     
     
         7 . The composition of  claim 1 , wherein the ionic liquid has a cation:anion ratio of 1:1. 
     
     
         8 . The composition of  claim 1 , wherein the composition does not comprise an active agent other than the at least one ionic liquid. 
     
     
         9 . The composition of  claim 1 , wherein the composition is formulated for ocular administration. 
     
     
         10 . The composition of  claim 1 , further comprising one or more additional antifungal agents. 
     
     
         11 . The composition of  claim 10 , wherein the one or more additional antifungal agents are selected from the group consisting of:
 Amphotericin B; natamycin; voriconazole; povidone-iodine; hypochlorous acid;   Chlorhexidine digluconate (CDG); vancomycin (VAN); chloramphenicol (CHL);   polymyxin B (PMB); trimethoprim (TMP); benzalkonium chloride (BAK); and   combinations thereof.   
     
     
         12 - 20 . (canceled) 
     
     
         21 . The composition of  claim 1 , wherein the composition comprises a therapeutically effective amount of the at least one ionic liquid to treat a fungal infection in a subject in need thereof. 
     
     
         22 . The composition of  claim 21 , wherein the fungal infection is an ocular fungal infection. 
     
     
         23 . The composition of  claim 21 , wherein the subject has received a corneal surgery. 
     
     
         24 . The composition of  claim 23 , wherein the surgery is artificial cornea surgery. 
     
     
         25 . The composition of  claim 21 , wherein the fungal infection is infectious keratitis and/or endopthalmitis. 
     
     
         26 . The composition of  claim 21 , wherein the fungal infection is an infection of  Candida ,  Candida albicans ,  Candida parapsilosis ,  Fusarium , or  Aspergillus . 
     
     
         27 . The composition of  claim 21 , wherein the composition is effective to treat the fungal infection in the subject by daily administration to the subject. 
     
     
         28 . The composition of  claim 21 , wherein the composition is formulated in or on a contact lens, a lower conjunctival fornix device, or a subconjunctival device.